What is it about?
This is a single institution population-based study including all newly diagnosed patients diagnosed with multiple myeloma during 31 years. Early mortality is a key obstacle to improve the outcome in myeloma. The time-dependent impact of comorbidity in early mortality is shown. A standardized approach is suggested in order to allow to comparison between studies. Infection remains the most frequent cause of death in this disease. Therefore, every effort should be made to avoid this common complication
Featured Image
Why is it important?
Data about comorbidity outside clinical trials are scarce. Population-based registries can add important information about the outcome of real-life patients with myeloma
Perspectives
We cannot improve what we dont know. We have to measure the outcome of every patient in terms of quality of life, progression free survival and overall survival. Every effort should be made to avoid early mortality in myeloma. A comprehensive and dynamic approach to comorbidity is suggested.
Dr Rafael Rios Tamayo
International Air and Hospitality Academy
Read the Original
This page is a summary of: Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients, American Journal of Hematology, April 2016, Wiley,
DOI: 10.1002/ajh.24389.
You can read the full text:
Contributors
The following have contributed to this page
